Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety and tolerability of dimebon given to Alzheimer's disease patients currently on a stable dose and regimen of memantine or memantine plus donepezil.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Medivation, Inc.
NCT05592678 · Alzheimer's Disease (AD), Dementia, and more
NCT07033494 · Early Alzheimer's Disease
NCT06159673 · Alzheimer's Disease Psychosis
NCT07457138 · Subjective Cognitive Decline (SCD), Functional Cognitive Disorder, and more
NCT07422857 · Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia
Los Alamitos, California
National City, California
Delray Beach, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions